Page 22 - The DHEA Debate - Life Extensions Magazine

63. Sacco M, Valenti G, Corvi Mora P, Wu FC, Ray DW. DHEA, a selective glucocorticoid
receptor antagonist: its role in immune system regulation and metabolism. J Endocrinol Invest.
2002;25(10 Suppl):81-2.

64. Bradlow HL, Sepkovic DW. Diet and breast cancer. Ann NY Acad Sci. 2002 Jun;963:247-67.
65. Mei JJ, Hursting SD, Perkins SN, Phang JM. p53-independent inhibition of nitric oxide
generation by cancer preventive interventions in ex vivo mouse peritoneal macrophages.
Cancer Lett. 1998 Jul 17;129(2):191-7.

66. D’Ambrosio SM, Gibson-D’Ambrosio RE, Wani G, et al. Modulation of Ki67, p53 and
RARbeta expression in normal, premalignant and malignant human oral epithelial cells by
chemopreventive agents. Anticancer Res. 2001 Sep-Oct;21(5):3229- 35.

67. Weber E, Moore MA, Bannasch P. Phenotypic modulation of hepatocarcinogenesis and
reduction in N-nitrosomor- pholine-induced hemangiosarcoma and adrenal lesion development
in Sprague- Dawley rats by dehydroepiandrosterone. Carcinogenesis. 1988 Jul;9(7):1191-5.
68. Prough RA, Lei XD, Xiao GH, Wu HQ, Geoghegan TE, Webb SJ. Regulation of cytochrome
P450 by DHEA and its anticarcinogenic action. Ann NY Acad Sci. 1995 Dec 29;774:187-99.
69. Schwartz AG, Pashko LL. Cancer prevention with DHEA and nonandrogenic structural
analogs. J Cell Biochem Suppl.1995;22:210-217.
70. Inano H, Ishii-Ohba H, Suzuki K, Yamanouchi H, Onoda M, Wakabayashi K.
Chemoprevention by dietary dehydroepiandrosterone against promotion / progression phase of
radiation-induced mamary tumorigenesis in rats. J Steroid Biochem and Mol Biol. 1995 Jul;
54(1- 2):47-53.

71. Poetschke HL, Klug DB, Hursting SD, Richie ER. The effect of chemoprotective steroids on
thymocyte and thymic epithelial cell development. FASEB Journal. 1999; 13(4):A623.

72. Greenwald P, Kelloff GJ, Boone CW, McDonald SS. Genetic and cellular changes in
colorectal cancer: proposed targets of chemoprotective agents. Cancer Epidemiol Biomarkers
Prev. 1995 Oct-Nov; 4(7):691-702.

73. Melvin WS, Boros LG, Muscarella P, et al. Dehydroepiandrosterone-sulfate inhibits
pancreatic carcinoma cell proliferation in vitro and in vivo. Surgery. 1997 Apr;121(4):392-7.

74. Hursting SD, Perkins SN, Haines DC, Ward JM, Phang JM. Chenoprevention of
spontaneous tumorigenesis in p53 knock-out mice. Cancer Res. 1995 Sep; 15;55(18);3949-53.

75. Ledochowski M, Murr C, Jager M, Fuchs D. Dehydroepiandrosterone, ageing and immune
activation. Exp Gerontol. 2001 Nov; 36:1739-47.

76. Metzger C, Bannasch P, Mayer D. Enhancement and phenotypic modulation of N-
nitrosomorpholine-induced hepatocarcinogenesis by dehydroepiandrosterone. Cancer Lett.
1997 Dec 23;121(2):125-31.

77. Moore MA, Weber E, Thorton M, Bannasch P. Sex-dependent, tissue-specific opposing
effects of dehydroepiandrosterone on initiation and modulation stages of liver and lung
carcinogenesis induced by dihydroxy-di-n-propylnitrosamine in F344 rats. Carcinogenesis. 1988
Aug; 9(8):1507-9.

78. Williams JR. The effects of dehydroepiandrosterone on carcinogenesis, obesity, the immune
system and aging. Lipids. 2000 Mar; 35(3):325-31.